Clinical Trial

68Ga-PSMA-11 PET Imaging for Diagnosing Prostate Cancer, a Head-to-head Comparison With mpMRI

Recruiting Phase 2/3
View on ClinicalTrials.gov →
Record status
This record was last updated October 7, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
68Ga-PSMA-11 is a widely used radiotracer targeting PSMA. In this study, we investigated the diagnostic efficacy of 68Ga-PSMA-11 PET imaging (PET/CT or PET/MRI) in patients with newly diagnosed, treatment-naive prostate cancer, and performed a head-to-head comparison with multi-parameter magnetic resonance imaging (mpMRI).
Trial Details
NCT Number NCT07209878
Lead Sponsor First Affiliated Hospital of Fujian Medical University
Conditions Prostate Cancer (Adenocarcinoma)
Enrollment 100 participants
Start Date 2020-01-10
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-10-07